The 5 Most Interesting Analyst Questions From United Therapeutics's Q3 Earnings Call

United Therapeutics delivered a quarter that was well received by the market despite missing revenue expectations, as operational progress and clinical milestones took center stage. Management credited sales growth to continued expansion of the Tyvaso and Orenitram franchises, highlighting robust demand for Tyvaso DPI and minimal impact from new competition. CEO Martine Rothblatt emphasized that three Phase III trials reached full enrollment and that recently unblinded pulmonary fibrosis results represented “the best results for that condition ever reported by anyone, anywhere.” The quarter also benefited from commercial execution and new product features designed to enhance patient convenience.

Is now the time to buy UTHR? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From United Therapeutics’s Q3 Earnings Call

• Lisa Walter (RBC): Asked about the impact of TETON 2 results on diagnosis rates and Tyvaso sales. President Michael Benkowitz said it is too early to observe a direct uptick, but clinicians are increasingly aware and monitoring trends.

• Andreas Argyrides (Oppenheimer): Inquired about the market opportunity for ralinepag and expectations for advanced outcomes. CEO Martine Rothblatt highlighted the drug’s long patent life, strong trial results, and potential for synergistic combinations.

• Joseph Thome (TD Cowen): Asked about partnership strategies in the wake of recent IPF data. Rothblatt described openness to international partnerships, noting that United Therapeutics’ operations are largely U.S.-focused but that overseas opportunities are under consideration.

• Olivia Brayer (Cantor): Sought details on commercial dynamics for Tyvaso and competitive impacts. Benkowitz explained that new competition has grown disease awareness, helping expand the market rather than eroding share.

• Roanna Ruiz (Leerink): Requested launch details for the new 80-microgram Tyvaso DPI cartridge. EVP Patrick Poisson confirmed a near-term launch, stressing the convenience and dosing benefits for patients.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be tracking (1) regulatory progress for Tyvaso DPI in idiopathic pulmonary fibrosis, (2) adoption rates and prescriber feedback following the high-dose cartridge launch, and (3) advancement of the ralinepag outcomes trial and potential business development activity. Execution on international partnerships and updates from additional clinical studies will also be key indicators of United Therapeutics’ future trajectory.

United Therapeutics currently trades at $436.33, up from $414.93 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free for active Edge members).

Our Favorite Stocks Right Now

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.